1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomarkers Prev 2016;25:16-27.

2. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017;8:1-20.

3. Peters S, Reck M, Smit EF, Mok T, Hellmann MD. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Ann Oncol 2019;30:884-96.

4. Baxevanos P, Mountzios G. Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau? Ann Transl Med 2018;6:139.

5. Olaussen KA, Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol 2016;27:2004-16.

6. Wang C, Kulkarni P, Salgia R. Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. Mol Ther Oncolytics 2019;13:1-6.

7. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2016;2:46-54.

8. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.

9. Leighl NB, Hellmann MD, Hui R, Costa EC, Felip E, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol 2017;35:9011.

10. Herbst RS, Baas P, Kim D, Felip E, Pérez-Gracia JL, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50.

11. Jean F, Tomasini P, Barlesi F. Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy. Ther Adv Med Oncol 2017;9:769-79.

12. Wang L, Zhao D, Qin K, Rehman FU, Zhang X. Effect and biomarker of Nivolumab for non-small-cell lung cancer. Biomed Pharmacother 2019;117:109199.

13. Maleki Vareki S, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol 2017;116:116-24.

14. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-94.

15. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46.

16. Abdel-Rahman O, Morris D. Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update. Immunotherapy 2019;11:149-53.

17. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, et al; KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92.

18. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508.

19. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378:2288-301.

20. Cappuzzo F, Mccleod M, Hussein M, Morabito A, Rittmeyer A, et al. IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol 2018;29:viii742-3.

21. Barlesi F, Nishio M, Cobo M, Steele N, Paramonov V, et al. IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Ann Oncol 2018;29:viii743-4.

22. Lopes G, Wu Y, Kudaba I, Kowalski D, Cho BC, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 2018;36:LBA4.

23. Paz-ares LG, Luft A, Tafreshi A, Gumus M, Mazieres J, et al. Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). JCO 2018;36:105-105.

24. Wan N, Zhang TT, Hua SH, Lu ZL, Ji B, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. Cancer Med 2020;9:1683-93.

25. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015;28:690-714.

26. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013;39:74-88.

27. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011;30:61-9.

28. Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology 2017;6:e1331807.

29. Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016;34:2969-79.

30. Gadgeel SM, Stevenson J, Langer CJ, Gandhi L, Borghaei H, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. JCO 2016;34:9016-9016.

31. Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, et al. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer 2018;101:114-22.

32. Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, et al. Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study. J Clin Oncol 2017;35:9092-9092.

33. Li JX, Huang JM, Jiang ZB, Li RZ, Sun A, et al. Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. Integr Cancer Ther 2019;18:1534735419890020.

34. Apetoh L, Ladoire S, Coukos G, Ghiringhelli F. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 2015;26:1813-23.

35. Qiao M, Jiang T, Ren S, Zhou C. Combination strategies on the basis of immune checkpoint inhibitors in non-small-cell lung cancer: where do we stand? Clin Lung Cancer 2018;19:1-11.

36. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010;102:115-23.

37. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21.

38. Larsson AM, Roxå A, Leandersson K, Bergenfelz C. Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer. Sci Rep 2019;9:13451.

39. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011;121:3100-8.

40. Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 2013;8:e61895.

41. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.

42. Leonetti A, Wever B, Mazzaschi G, Assaraf YG, Rolfo C, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat 2019;46:100644.

43. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2’-deoxycytidine treatment. Int J Cancer 2001;94:243-51.

44. Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016;44:343-54.

45. Ganss R, Ryschich E, Klar E, Arnold B, Hämmerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002;62:1462-1470.

46. Rettig L, Seidenberg S, Parvanova I, Samaras P, Curioni A, et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer 2011;129:832-8.

47. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 2017;168:707-23.

48. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.

49. Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res 2014;20:6593-604.

50. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 2016;6:827-37.

51. Tun AM, Thein KZ, Thein WL, Guevara E. Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Future Sci OA 2019;5:FSO421.

52. Dafni U, Tsourti Z, Vervita K, Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer 2019;134:127-40.

53. Addeo A, Banna GL, Metro G, Di Maio M. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. Front Oncol 2019;9:264.

54. Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett 2018;419:210-21.

55. Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, et al. Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung cancer. Oncologist 2020;25:64-77.

56. Yan Y, Kumar AB, Finnes H, Markovic SN, Park S, et al. Combining immune checkpoint inhibitors with conventional cancer therapy. Front Immunol 2018;9:1739.

57. Rassy E, Bakouny Z, Assi T, Karak FE, Pavlidis N. The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism? Immunotherapy 2019;11:913-20.

58. Coffelt SB, de Visser KE. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol 2015;36:198-216.

59. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24:75-83.

60. Reck M, Shankar G, Lee A, Coleman S, McCleland M, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Rev Respir Med 2020;14:125-36.

61. Ogawara D, Soda H, Iwasaki K, Suyama T, Taniguchi H, et al. Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy. Thorac Cancer 2018;9:175-80.

62. Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol 2018;13:106-11.

63. Saleh R, Elkord E. Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett 2019;457:168-79.

64. Vera Aguilera J, Paludo J, McWilliams RR, Zhang H, Li Y, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res 2020; doi: 10.1097/CMR.0000000000000669.

65. Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 2018;3:97828.

66. Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, et al. Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed) 2012;4:958-75.

67. Chang CL, Hsu YT, Wu CC, Lai YZ, Wang C, et al. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res 2013;73:119-27.

68. Chatwal MS, Tanvetyanon T. Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine? Transl Lung Cancer Res 2018;7:S208-10.

Cancer Drug Resistance
ISSN 2578-532X (Online)


All published articles will preserved here permanently:


All published articles will preserved here permanently: